Keith W. Roach, MD, is an associate professor of clinical medicine in the division of general medicine at NewYork-Presbyterian. Christopher Kelly, MD, from UNC Health, is a general cardiologist who ...

—A new study of more than 42,000 patients sought to evaluate contemporary trends in testing for biomarkers of non-small cell lung cancer (NSCLC), as well as rates of treatment with ...

Every year, America’s medical research pipeline produces new treatments, new technologies and new ways to improve patient care. Often, the real challenge is ensuring policy keeps pace with these ...

Only 35% of advanced cancer patients received comprehensive genomic profiling testing. Tested patients were more likely to receive targeted therapies. Testing rates increased slightly over time and ...

Imagine this: someone you love has just heard the words “you have cancer.” They are meeting with their oncologist – perhaps even me, or one of my colleagues – and come to understand that there is ...

A panelist discusses how folate receptor alpha (FRα) expression testing plays a crucial role in determining eligibility for mirvetuximab soravtansine (an antibody-drug conjugate therapy), emphasizing ...

Almost all of us have been touched by cancer at some point in our lives. If we haven’t had it, chances are we know a loved one or a friend who has. When someone dies from cancer, families go through ...

We tried out one of the most advanced baseline diagnostic panels available – here’s what we discovered about our health with this biomarker testing… Preventative healthcare has long been the preserve ...

Three years ago, New York state took a huge step forward by expanding access to biomarker testing, which is said to be a game changer in cancer care. Now, however, advocates fear the state could be ...